A Randomized, Double-Blinded, Placebo-Controlled Study of the Effect of XmAb®5871 on Systemic Lupus Erythematosus Disease Activity
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 13 Mar 2018
At a glance
- Drugs XmAb 5871 (Primary)
- Indications Immunological disorders; Systemic lupus erythematosus
- Focus Therapeutic Use
- Sponsors Xencor
- 27 Feb 2018 According to a Xencor media release, company expect to announce initial data from this study in 4Q of 2018.
- 05 Jan 2018 According to a Xencor media release, enrollment was completed in the Phase 2 trial in SLE in December 2017.
- 05 Jan 2018 Status changed from recruiting to active no longer recruiting, according to a Xencor media release.